Header Logo

Connection

JOSEPH KHOURY to Leukemia, Myeloid, Acute

Back to Details
This is a "connection" page, showing publications JOSEPH KHOURY has written about Leukemia, Myeloid, Acute.
JOSEPH KHOURY
Connection Strength
3.662
Leukemia, Myeloid, Acute
  1. Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope. Leuk Res. 2024 02; 137:107441.
    View in: PubMed
    Score: 0.226
  2. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022 07 07; 140(1):58-72.
    View in: PubMed
    Score: 0.203
  3. Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy. Leuk Res. 2022 07; 118:106860.
    View in: PubMed
    Score: 0.201
  4. Microsatellite Instability Assessment by Immunohistochemistry in Acute Myeloid Leukemia: A Reappraisal and Review of the Literature. Clin Lymphoma Myeloma Leuk. 2022 06; 22(6):e386-e391.
    View in: PubMed
    Score: 0.195
  5. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. Blood Cancer J. 2018 10 19; 8(11):98.
    View in: PubMed
    Score: 0.157
  6. P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. Am J Hematol. 2018 11; 93(11):1376-1383.
    View in: PubMed
    Score: 0.156
  7. Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S85-90.
    View in: PubMed
    Score: 0.124
  8. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment. Leukemia. 2016 Jan; 30(1):242-7.
    View in: PubMed
    Score: 0.124
  9. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 04; 7:74.
    View in: PubMed
    Score: 0.119
  10. Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. J Hematol Oncol. 2014 Mar 27; 7:26.
    View in: PubMed
    Score: 0.114
  11. Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement. Am J Clin Pathol. 2024 Nov 04; 162(5):455-463.
    View in: PubMed
    Score: 0.060
  12. Can molecular patterns help to classify overlapping entities in myeloid neoplasms? Histopathology. 2025 Jan; 86(1):146-157.
    View in: PubMed
    Score: 0.060
  13. Age-specific induction of mutant p53 drives clonal hematopoiesis and acute myeloid leukemia in adult mice. Cell Rep Med. 2024 May 21; 5(5):101558.
    View in: PubMed
    Score: 0.058
  14. Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). Blood Cancer J. 2024 02 05; 14(1):25.
    View in: PubMed
    Score: 0.057
  15. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood Cancer J. 2024 01 25; 14(1):19.
    View in: PubMed
    Score: 0.057
  16. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 2024 03; 38(3):545-556.
    View in: PubMed
    Score: 0.056
  17. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms. Mod Pathol. 2024 Feb; 37(2):100397.
    View in: PubMed
    Score: 0.056
  18. Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res. 2023 11 01; 29(21):4352-4360.
    View in: PubMed
    Score: 0.056
  19. A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis. Blood Cancer J. 2023 06 29; 13(1):101.
    View in: PubMed
    Score: 0.054
  20. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies. Mod Pathol. 2023 06; 36(6):100166.
    View in: PubMed
    Score: 0.053
  21. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia. 2022 11; 36(11):2729-2733.
    View in: PubMed
    Score: 0.052
  22. PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia. Genes (Basel). 2022 07 29; 13(8).
    View in: PubMed
    Score: 0.051
  23. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica. 2022 06 01; 107(6):1311-1322.
    View in: PubMed
    Score: 0.050
  24. Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine. Leuk Res. 2022 08; 119:106884.
    View in: PubMed
    Score: 0.050
  25. Prediction of survival with intensive chemotherapy in acute myeloid leukemia. Am J Hematol. 2022 07; 97(7):865-876.
    View in: PubMed
    Score: 0.050
  26. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022 02 10; 139(6):907-921.
    View in: PubMed
    Score: 0.049
  27. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells. Blood Cancer J. 2022 01 31; 12(1):23.
    View in: PubMed
    Score: 0.049
  28. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022 01 11; 12(1):5.
    View in: PubMed
    Score: 0.049
  29. Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. Am J Hematol. 2022 03 01; 97(3):329-337.
    View in: PubMed
    Score: 0.049
  30. Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2022 03; 57(3):370-376.
    View in: PubMed
    Score: 0.049
  31. Development of TP53 mutations over the course of therapy for acute myeloid leukemia. Am J Hematol. 2021 11 01; 96(11):1420-1428.
    View in: PubMed
    Score: 0.048
  32. Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy. Cold Spring Harb Mol Case Stud. 2021 06; 7(3).
    View in: PubMed
    Score: 0.047
  33. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 05 20; 11(5):98.
    View in: PubMed
    Score: 0.047
  34. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.
    View in: PubMed
    Score: 0.047
  35. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol. 2021 03; 192(6):1054-1063.
    View in: PubMed
    Score: 0.046
  36. Germline DNMT3A mutation in familial acute myeloid leukaemia. Epigenetics. 2021 05; 16(5):567-576.
    View in: PubMed
    Score: 0.045
  37. Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leuk Lymphoma. 2020 12; 61(13):3243-3246.
    View in: PubMed
    Score: 0.044
  38. Myeloid diseases in the lung and pleura. Semin Diagn Pathol. 2020 Nov; 37(6):296-302.
    View in: PubMed
    Score: 0.044
  39. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies. Curr Hematol Malig Rep. 2020 06; 15(3):194-202.
    View in: PubMed
    Score: 0.044
  40. Mechanistic basis and efficacy of targeting the ?-catenin-TCF7L2-JMJD6-c-Myc axis to overcome resistance to BET inhibitors. Blood. 2020 04 09; 135(15):1255-1269.
    View in: PubMed
    Score: 0.043
  41. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020 09; 33(9):1678-1689.
    View in: PubMed
    Score: 0.043
  42. Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy. Am J Hematol. 2020 06; 95(6):612-622.
    View in: PubMed
    Score: 0.043
  43. Genome-wide analysis of acute leukemia and clonally related histiocytic sarcoma in a series of three pediatric patients. Pediatr Blood Cancer. 2020 02; 67(2):e28074.
    View in: PubMed
    Score: 0.042
  44. RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1. Blood. 2019 07 04; 134(1):59-73.
    View in: PubMed
    Score: 0.041
  45. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer J. 2019 01 15; 9(2):4.
    View in: PubMed
    Score: 0.040
  46. Targeting nuclear ?-catenin as therapy for post-myeloproliferative neoplasm secondary AML. Leukemia. 2019 06; 33(6):1373-1386.
    View in: PubMed
    Score: 0.040
  47. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia. 2019 04; 33(4):931-944.
    View in: PubMed
    Score: 0.039
  48. Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. Am J Surg Pathol. 2018 05; 42(5):569-577.
    View in: PubMed
    Score: 0.038
  49. Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations. Br J Haematol. 2018 05; 181(3):305.
    View in: PubMed
    Score: 0.037
  50. Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms. Haematologica. 2017 12; 102(12):2048-2057.
    View in: PubMed
    Score: 0.036
  51. Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype. Cancer Genet. 2016 Jul-Aug; 209(7-8):313-20.
    View in: PubMed
    Score: 0.033
  52. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genet. 2015 Nov; 208(11):571-4.
    View in: PubMed
    Score: 0.031
  53. MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation. Hum Pathol. 2015 Jan; 46(1):65-73.
    View in: PubMed
    Score: 0.030
  54. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013 Dec; 88(12):1055-61.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.